Cue Biopharma, Inc. (CUE) has 15 SEC Form 4 insider filings on record in the last 90 days. Most recent filing: Aug. 28, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Aug. 28, 2026 filed July 9, 2026 | Sarraf Pasha Director | $0 | 18,400 | +170% | No | |
|
|
||||||
| Aug. 28, 2026 filed July 9, 2026 | Garzone Pamela Director | $0 | 18,900 | New | No | |
|
|
||||||
| Aug. 17, 2026 filed Aug. 13, 2026 | Ray Sumita Chief Legal Compliance Officer | — | +9,367 | +35% | No | |
|
|
||||||
| Aug. 17, 2026 filed Aug. 13, 2026 | Meluzio Michael Vincent VP, Prin. Accounting Officer | — | +8,019 | +42% | No | |
|
|
||||||
| Aug. 14, 2026 filed Aug. 12, 2026 | Lin Shao-Lee Chief Executive Officer | — | +50,921 | +8% | No | |
|
|
||||||
Showing the 5 most recent of 15 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free